uploads///Chart  ZTS

Performance of Zoetis Stock in 2Q17

By

Jul. 10 2017, Published 12:46 p.m. ET

A look at Zoetis

Headquartered in Parsippany, New Jersey, Zoetis (ZTS) is one of the largest pharmaceutical companies that produce drugs and vaccinations for animals. It operates in more than 70 countries worldwide. The products and services offered by Zoetis are classified into farm animal products, companion animal products, animal diagnostics, and animal genetics.

Article continues below advertisement

Stock price performance

Zoetis (ZTS) stock has risen ~17.3% in 2Q17, while it has risen ~15.4% year-to-date as of July 7, 2017.

Analyst recommendations

Wall Street analysts estimate that Zoetis stock has the potential to rise ~5.7% over the next 12 months. Analyst recommendations show a 12-month target price of $65.31 per share compared to the last price of $61.79 on July 6, 2017.

There are 20 analysts tracking Zoetis stock. Of those, 15 analysts are recommending a “buy,” while five are recommending a “hold.” The consensus rating for Zoetis stands at 1.9, which represents a “strong buy” for long-term investors and momentum investors.

Analysts’ revenue estimates

Zoetis’s revenues are mainly driven by the strong performance of companion animal and farm animal products.

Wall Street analyst estimates show revenues of $1.3 billion in 2Q17, which is a ~4.7% rise compared to 2Q16, and EPS (earnings per share) of $0.53 for the quarter.

To divest the company-specific risks, you can consider the iShares US Pharmaceuticals (IHE), which holds 4.1% of its total assets in Zoetis. IHE also holds 9.4% in Johnson & Johnson (JNJ), 5.6% in Bristol-Myers Squibb (BMY), and 6.1% in Eli Lilly (LLY).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.